Drug Discovery
This section features DDW articles on drug discovery and drug development.
Page 14 to 28 of 64 |   < PREVIOUS PAGE   NEXT PAGE >
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu Winter 16/17
As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians to push away the originating basic scientists, lest their lofty impractical ideals disrupt a delicate balance of strategic compromise. Indeed many scientists may not understand the competing push and pull of efficacy versus toxicity and quality versus production costs.

Read More

Ion Channels - increasingly enticing targets for drug discovery by Dr Douglas Krafte and Deborah Erickson Summer 2016
Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease.

Read More

Reigniting pharmaceutical innovation through holistic drug targeting By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Summer 2016
Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic.

Read More

Drug Discovery in a Multi-Omics World By Mike Furness Winter 2015/16
Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part IV: Financial model and analysis By David M. Kauppi and Dr Stephen Naylor Winter 2015/16
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) impacts all stakeholders involved in the therapeutic drug sector.

Read More

When two are not enough: lead optimisation beyond matched pairs By Dr Noel M. O'Boyle, Dr Roger A. Sayle and Dr Matt Segall Fall 2015
Lead optimisation projects progress by making successive enhancements to one or more starting structures. This is a classic multi-objective optimisation procedure where the goal is not only to improve potency but also to improve physicochemical and ADME properties.

Read More

The increasing impact of precision research models on drug discovery and development Dr Amar Thyagarajan Fall 2015
Animal models are the standard by which we gain insight into the complex biological processes that underlie normal human physiology and disease states. Rodent models such as rats and mice have been used to understand various aspects of human physiology, disease and treatment outcomes.

Read More

How neutron science has enabled innovation in drug design and delivery By Dr Giovanna Fragneto Fall 2015
Meeting global health challenges, from cancer to viral infections, requires a profound understanding of living processes – not just at the level of cells but right down at the molecular level. And designing the most efficient therapeutics requires an in-depth understanding of the disease.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part III market exclusivity using Intellectual Property and regulatory pathways By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld Summer 2015
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned stakeholders. In part this is due to the fact that the pharmaceutical industry now accrues ~25% of its annual revenues from DRPx products.

Read More

Therapeutic Drug Repurposing: repositioning and rescue By Dr Stephen Naylor & Judge M. Schonfeld Winter 2014
The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug sector, and patients that have morphed into a discerning consumer population.

Read More

The many roads to cell death: discriminating between apoptosis, necrosis & autophagy By Dr John Abrams, Dr William G. Telford & Louise Rollins Winter 2014
Cell death is crucial for the proper execution of normal and pathophysiological processes and is ubiquitous in biological systems.

Read More

A novel approach by AstraZeneca to monitor primary DMPK assay performance & understand the inter and intra site assay variability By Dr Claire Landqvist, Brian Middleton, Dr Barry Jones and Dr Charles O’Donnell Drug Fall 14
An integral part of early drug discovery at AstraZeneca is the process known as the Design Make Test Analyse (DMTA) Cycle. DMTA relies heavily on chemical synthesis and primary screening being delivered within a quick turnaround time.

Read More

Automated patch clamping finally achieves high throughput! By Dr John Comley Fall 14
Two new third-generation automated patch clamp (APC) systems capable of high throughput processing (10,000 data points per eight-hour day) and full robotic integration have been recently launched. The resulting wider choice of primarily 384 APC systems has the potential to intensify competition in the market for APC consumables (patch plates).

Read More

Drug Discovery
Page 14 to 28 of 64 |   < PREVIOUS PAGE   NEXT PAGE >